MANBA

Beta-mannosidase · O00462 · MANBA on Sugi Atlas →

909 patent compounds predicted against MANBA, 492 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Gluconolactone (SCHEMBL10823227)	0.39	3/20
Gluconolactone (SCHEMBL11053856)	0.39	3/20
SCHEMBL8588768	0.34	3/20
SCHEMBL8198571	0.34	3/20
SCHEMBL20788789	1.00	2/20
Gluconolactone (SCHEMBL15320)	0.47	2/20
Gluconolactone (SCHEMBL221828)	0.47	2/20
Gluconolactone (SCHEMBL333412)	0.47	2/20
Gluconolactone (SCHEMBL2214579)	0.47	2/20
Gluconolactone (SCHEMBL2461264)	0.47	2/20
Gluconolactone (SCHEMBL2464302)	0.47	2/20
Gluconolactone (SCHEMBL2466355)	0.47	2/20
Gluconolactone (SCHEMBL2466472)	0.47	2/20
Gluconolactone (SCHEMBL2468364)	0.47	2/20
Gluconolactone (SCHEMBL7148519)	0.47	2/20
Gluconolactone (SCHEMBL7152056)	0.47	2/20
Gluconolactone (SCHEMBL10173017)	0.47	2/20
Gluconolactone (SCHEMBL10221981)	0.47	2/20
Gluconolactone (SCHEMBL12377168)	0.47	2/20
Gluconolactone (SCHEMBL13176828)	0.47	2/20

Clinical trials — most relevant to MANBA by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Pharmacokinetics of Alglucosidase Alfa in Patients With Pompe Disease	PHASE4	COMPLETED
High Dose or High Dose Frequency Study of Alglucosidase Alfa	PHASE4	COMPLETED
Interventional Study to Assess Efficacy and Safety of Velmanase Alfa in Patients With Alpha Mannosidosis	PHASE3	WITHDRAWN
A Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) Enzyme Replacement Therapy in Gaucher Disease	PHASE3	COMPLETED
Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) ERT Compared With Imiglucerase in Type I Gaucher Disease	PHASE3	COMPLETED
Study of GA-GCB Enzyme Replacement Therapy in Type 1 Gaucher Disease Patients Previously Treated With Imiglucerase	PHASE2/PHASE3	COMPLETED
A Placebo-Controlled Phase 3 Trial of Repeated Lamazym Treatment of Subjects With Alpha-Mannosidosis	PHASE3	COMPLETED
An Open-Label Extension Study of GA-GCB ERT in Patients With Type 1 Gaucher Disease	PHASE3	COMPLETED
Dose Finding Study of Recombinant Human Alpha-mannosidase for the Treatment of Patients With Alpha-mannosidosis	PHASE2	UNKNOWN
Study of Safety, Tolerability and Efficacy of PBGM01 in Pediatric Participants With GM1 Gangliosidosis	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
Trial on Safety and Efficacy of Velmanase Alfa Treatment in Pediatric Patients With Alpha-Mannosidosis	PHASE2	COMPLETED
Long-term Efficacy and Safety of Lamazym for the Treatment of Patients With Alpha-Mannosidosis	PHASE2	COMPLETED
Recombinant Human Mannose-Binding Lectin (MBL) in Treating Young Patients With MBL Deficiency and Fever and Neutropenia	PHASE1	WITHDRAWN
A Study of Safety, Tolerability, and Pk of rhMBL in Pediatric Hematology/Oncology Pts With Fever and Neutropenia	PHASE1	WITHDRAWN
Biomarker for Mannosidosis Disease (BioMannosidosis)	nan	WITHDRAWN
The Natural History of Alpha-Mannosidosis	nan	COMPLETED
Lyso-Gb1 as a Long-term Prognostic Biomarker in Gaucher Disease	nan	COMPLETED
Registry Gangliosidoses	nan	UNKNOWN
Analysis of Velmanase Alfa (Lamzede®)'s Effects in the Body of Children With Alpha-Mannosidosis Under the Age 3	nan	RECRUITING
Biomarker for Mucolipidosis Disorder Type I, II, III, IV (BioML)	nan	WITHDRAWN
Effect of Migalastat on Cardiac Involvement in Fabry Disease	nan	COMPLETED
A Study to Evaluate and Characterize the Effect of Pharmacological Chemicals on Blood From Patients With Gaucher Disease	nan	COMPLETED
Study to Collect Data on Fabry Disease Patients With Enhanceable Alpha-Galactosidase A Activity	nan	COMPLETED
Treatment Protocol of Velaglucerase Alfa for Patients With Type 1 Gaucher Disease	nan	APPROVED_FOR_MARKETING
Biomarker for Gangliosidosis: BioGM1/BioGM2 (BioGM1/GM2)	nan	WITHDRAWN
Expanded Access Use of Myozyme (Alglucosidase Alfa) in Patients With Infantile-onset Pompe Disease	nan	APPROVED_FOR_MARKETING
BMN 110 US Expanded Access Program	nan	APPROVED_FOR_MARKETING
Characterization of the Patient Population With Galactosialidosis	nan	COMPLETED
Screening of Fabry Disease in Patients With GI Symptoms	nan	UNKNOWN
Clinical Biomarkers in Alpha-mannosidosis	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a MANBA binder may also engage these)

Protein	Name	Similarity
Q29444	—	1.000	Q29444 →
Q8K2I4	—	1.000	Q8K2I4 →
Q95327	—	1.000	Q95327 →
Q4FZV0	—	0.994	Q4FZV0 →
Q5R5N6	—	0.984	Q5R5N6 →
O77695	—	0.984	O77695 →
O97524	—	0.982	O97524 →
GUSB	Beta-glucuronidase	0.981	landscape →
Q4FAT7	—	0.981	Q4FAT7 →
O18835	—	0.979	O18835 →
P12265	—	0.978	P12265 →
FUCA2	Plasma alpha-L-fucosidase	0.976	landscape →
P06760	—	0.976	P06760 →
Q99KR8	—	0.975	Q99KR8 →
Q9FNA3	—	0.974	Q9FNA3 →
Q5RFI5	—	0.974	Q5RFI5 →
HEXA	Beta-hexosaminidase subunit alpha	0.972	landscape →
Q6DYE8	—	0.971	Q6DYE8 →
W8E7D1	—	0.971	W8E7D1 →
P70665	—	0.971	P70665 →
Q2M3T9	—	0.970	Q2M3T9 →
Q6AYS4	—	0.970	Q6AYS4 →
P97675	—	0.970	P97675 →
Q5RFU0	—	0.970	Q5RFU0 →
Q10RB4	—	0.970	Q10RB4 →
O95498	—	0.970	O95498 →
Q8BHN3	—	0.969	Q8BHN3 →
Q6AXR4	—	0.969	Q6AXR4 →
Q641Z7	—	0.969	Q641Z7 →
Q8GX69	—	0.969	Q8GX69 →